The patient was treated with 8 mg Lenvatinib, which resulted in serum FGF19 increasing significantly (ratio: 4.10) and Ang-2 decreasing (ratio 0.37) at 4 weeks, reduction of tumor volume and a partial therapeutic response (PR) according to mRECIST guidelines using CT images after 8 weeks (b). The gene discussed is ANGPT2; the disease is neoplasm.